B-type natriuretic peptide and heart failure: what can we learn from clinical trials?

Autor:	Christian Binoun-A-Egom, Peter Kruzliak, Angelo Andreas, Emmanuel E. Egom, Jan Klimas, Vanda Valentova
Rok vydání:	2015
Předmět:	medicine.medical_specialty Physiology medicine.drug_class Renal function Clinical science Diuresis 030204 cardiovascular system & hematology Natriuresis law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Physiology (medical) Internal medicine medicine Natriuretic peptide Intensive care medicine 030304 developmental biology Pharmacology 0303 health sciences business.industry medicine.disease 3. Good health Clinical trial Heart failure Cardiology business hormones hormone substitutes and hormone antagonists
Zdroj:	Clinical and experimental pharmacologyphysiology. 42(9)
ISSN:	1440-1681
Popis:	Summary The B-type natriuretic peptide (BNP) may favour natriuresis and diuresis, making it an ideal drug to aid in diuresing a fluid-overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these has resulted in a better outcome. The current challenge for BNP research in acute HF lies in a failure of concept and reluctance to abandon a demonstrably ineffectual research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP as well as a better integration of basic and clinical science.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3be1a4a1a1afd4e22ca4ad7bfc220c4 https://pubmed.ncbi.nlm.nih.gov/25969125 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.